

# Keertan Dheda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1297392/publications.pdf>

Version: 2024-02-01

283  
papers

26,675  
citations

9756

73  
h-index

7718

150  
g-index

292  
all docs

292  
docs citations

292  
times ranked

30835  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chest X-ray Analysis With Deep Learning-Based Software as a Triage Test for Pulmonary Tuberculosis: An Individual Patient Data Meta-Analysis of Diagnostic Accuracy. <i>Clinical Infectious Diseases</i> , 2022, 74, 1390-1400.	2.9	35
2	Treatment Response in Pediatric Pulmonary Tuberculosis—A Prospective Longitudinal Study. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 329-336.	0.6	1
3	An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1214-1227.	2.5	38
4	The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. <i>Lancet Respiratory Medicine</i> , 2022, 10, 603-622.	5.2	99
5	Accelerate investment and action to find the missing patients with tuberculosis. <i>Lancet</i> , 2022, 399, 2086-2088.	6.3	3
6	Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. <i>Lancet HIV</i> , 2022, 9, e309-e322.	2.1	38
7	High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence. <i>HIV Medicine</i> , 2022, 23, 1085-1097.	1.0	2
8	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet</i> , 2021, 397, 99-111.	6.3	3,887
9	Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1169, 122467.	1.2	3
10	Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. <i>The Cochrane Library</i> , 2021, 2021, CD012768.	1.5	63
11	Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting. <i>BMC Infectious Diseases</i> , 2021, 21, 99.	1.3	3
12	“You’re only there on the phone”—A qualitative exploration of community, affect and agential capacity in HIV self-testing using a smartphone app. <i>Sociology of Health and Illness</i> , 2021, 43, 591-606.	1.1	8
13	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet</i> , 2021, 397, 881-891.	6.3	979
14	The child ecosystem and childhood pulmonary tuberculosis: A South African perspective. <i>Pediatric Pulmonology</i> , 2021, 56, 2212-2222.	1.0	1
15	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1899-1909.	13.9	541
16	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1885-1898.	13.9	1,077
17	The Frequency and Effect of Granulocytic Myeloid-Derived Suppressor Cells on Mycobacterial Survival in Patients With Tuberculosis: A Preliminary Report. <i>Frontiers in Immunology</i> , 2021, 12, 676679.	2.2	8
18	Profiles of Volatile Biomarkers Detect Tuberculosis from Skin. <i>Advanced Science</i> , 2021, 8, e2100235.	5.6	31

#	ARTICLE	IF	CITATIONS
19	Profiles of Volatile Biomarkers Detect Tuberculosis from Skin (Adv. Sci. 15/2021). <i>Advanced Science</i> , 2021, 8, 2170093.	5.6	4
20	Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0138121.	1.4	9
21	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. <i>Lancet HIV</i> , 2021, 8, e568-e580.	2.1	124
22	Impact of a personalised, digital, HIV self-testing app-based program on linkages and new infections in the township populations of South Africa. <i>BMJ Global Health</i> , 2021, 6, .	2.0	1
23	Impact of a personalised, digital, HIV self-testing app-based program on linkages and new infections in the township populations of South Africa. <i>BMJ Global Health</i> , 2021, 6, e006032.	2.0	17
24	Bronchial Thermoplasty Global Registry (BTGR): 2-year results. <i>BMJ Open</i> , 2021, 11, e053854.	0.8	9
25	Alone But Supported: A Qualitative Study of an HIV Self-testing App in an Observational Cohort Study in South Africa. <i>AIDS and Behavior</i> , 2020, 24, 467-474.	1.4	21
26	A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2020, 55, 1901181.	3.1	30
27	A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-Guérin. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1277-1291.	2.5	28
28	The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study. <i>EclinicalMedicine</i> , 2020, 28, 100570.	3.2	152
29	An Optimal Diagnostic Strategy for Tuberculosis in Hospitalized HIV-Infected Patients Using GeneXpert MTB/RIF and Alere Determine TB LAM Ag. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	6
30	The Great Masquerader: Tuberculosis Presenting as Community-Acquired Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 592-604.	0.8	11
31	Challenging the management of drug-resistant tuberculosis – Authors' reply. <i>Lancet</i> , 2020, 395, 783-784.	6.3	1
32	Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis. <i>Nature Medicine</i> , 2020, 26, 1435-1443.	15.2	38
33	Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	2
34	Latent Tuberculosis Infection-associated Immunodiagnostic Test Responses as Biomarkers of Incipient Tuberculosis: Fruitful or Futile?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 895-898.	2.5	3
35	A landscape of genomic alterations at the root of a near-untreatable tuberculosis epidemic. <i>BMC Medicine</i> , 2020, 18, 24.	2.3	19
36	Comparison of Xpert MTB/RIF (G4) and Xpert Ultra, including trace readouts, for the diagnosis of pulmonary tuberculosis in a TB and HIV endemic setting. <i>International Journal of Infectious Diseases</i> , 2020, 95, 246-252.	1.5	15

#	ARTICLE	IF	CITATIONS
37	Differential RD-1-specific IFN- $\gamma$ host responses to diverse Mycobacterium tuberculosis strains in HIV-uninfected persons may be explained by genotypic variation in the ESX-1 region. <i>International Journal of Infectious Diseases</i> , 2020, 96, 240-243.	1.5	0
38	<i>kat</i> <sub>2</sub> -Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and <i>kat</i> <sub>2</sub> -Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	23
39	Diagnosis of COVID-19: Considerations, Controversies and Challenges in South Africa. <i>Wits Journal of Clinical Medicine</i> , 2020, 2, 3.	0.0	7
40	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. <i>Journal of Infection</i> , 2019, 78, 35-39.	1.7	30
41	Evaluating Latent Tuberculosis Infection Test Performance Using Latent Class Analysis in a TB and HIV Endemic Setting. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2912.	1.2	11
42	Same-Day Tools, Including Xpert Ultra and IRISA-TB, for Rapid Diagnosis of Pleural Tuberculosis: a Prospective Observational Study. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	32
43	Disrupting a cycle of mistrust: A constructivist grounded theory study on patient-provider trust in TB care. <i>Social Science and Medicine</i> , 2019, 240, 112578.	1.8	16
44	Recommendations for lung cancer screening in Southern Africa. <i>Journal of Thoracic Disease</i> , 2019, 11, 3696-3703.	0.6	16
45	Improving outcomes in patients with non-tuberculous mycobacterial disease: is there light at the end of the tunnel?. <i>European Respiratory Journal</i> , 2019, 54, 1901149.	3.1	0
46	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 820-826.	5.2	92
47	Urine lipoarabinomannan (LAM) and antimicrobial usage in seriously-ill HIV-infected patients with sputum smear-negative pulmonary tuberculosis. <i>Journal of Thoracic Disease</i> , 2019, 11, 3505-3514.	0.6	6
48	Management of drug-resistant tuberculosis. <i>Lancet</i> , The, 2019, 394, 953-966.	6.3	186
49	Relationship between chest radiographic characteristics, sputum bacterial load, and treatment outcomes in patients with extensively drug-resistant tuberculosis. <i>International Journal of Infectious Diseases</i> , 2019, 79, 65-71.	1.5	15
50	Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 370-380.	2.5	27
51	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. <i>The Lancet Global Health</i> , 2019, 7, e191-e199.	2.9	53
52	Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen. <i>International Journal of Infectious Diseases</i> , 2019, 85, 74-79.	1.5	21
53	Prospective Cohort Study on Performance of Cerebrospinal Fluid (CSF) Xpert MTB/RIF, CSF Lipoarabinomannan (LAM) Lateral Flow Assay (LFA), and Urine LAM LFA for Diagnosis of Tuberculous Meningitis in Zambia. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	33
54	Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation. <i>The Lancet Global Health</i> , 2019, 7, e798-e807.	2.9	33

#	ARTICLE	IF	CITATIONS
55	IL-4 subverts mycobacterial containment in <i>Mycobacterium tuberculosis</i> -infected human macrophages. <i>European Respiratory Journal</i> , 2019, 54, 1802242.	3.1	22
56	Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB. <i>ERJ Open Research</i> , 2019, 5, 00046-2019.	1.1	9
57	Once-a-week tigecycline for the treatment of drug-resistant TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1607-1617.	1.3	13
58	Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: Derivation and external validation cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002776.	3.9	23
59	Differential Targeting of c-Maf, Bach-1, and Elmo-1 by microRNA-143 and microRNA-365 Promotes the Intracellular Growth of <i>Mycobacterium tuberculosis</i> in Alternatively IL-4/IL-13 Activated Macrophages. <i>Frontiers in Immunology</i> , 2019, 10, 421.	2.2	37
60	Predictors of discordant latent tuberculosis infection test results amongst South African health care workers. <i>BMC Infectious Diseases</i> , 2019, 19, 131.	1.3	8
61	Guidance for Studies Evaluating the Accuracy of Biomarker-Based Nonsputum Tests to Diagnose Tuberculosis. <i>Journal of Infectious Diseases</i> , 2019, 220, S108-S115.	1.9	38
62	P032â€¦Alone but supported with an innovative HIV self-testing app: qualitative results from a large cohort study in south africa. , 2019, , .		0
63	Management of chronic obstructive pulmonary diseaseâ€”A position statement of the South African Thoracic Society: 2019 update. <i>Journal of Thoracic Disease</i> , 2019, 11, 4408-4427.	0.6	10
64	Transmission of drug-resistant tuberculosis in HIV-endemic settings. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e77-e88.	4.6	47
65	Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis. <i>Journal of Infectious Diseases</i> , 2019, 219, 975-985.	1.9	18
66	The Injectable Contraceptive Medroxyprogesterone Acetate Attenuates <i>Mycobacterium tuberculosis</i> â€”Specific Host Immunity Through the Glucocorticoid Receptor. <i>Journal of Infectious Diseases</i> , 2019, 219, 1329-1337.	1.9	7
67	Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	19
68	The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. <i>European Respiratory Journal</i> , 2019, 53, 1802089.	3.1	9
69	Does the use of adjunct urine lipopolysaccharide lipoarabinomannan in HIV-infected hospitalized patients reduce the utilization of healthcare resources? A post hoc analysis of the LAM multi-country randomized controlled trial. <i>International Journal of Infectious Diseases</i> , 2019, 79, 37-43.	1.5	1
70	An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 71-83.	2.0	23
71	Sleepiness score-specific outcomes of a novel tongue repositioning procedure for the treatment of continuous positive airway pressure-resistant obstructive sleep apnea. <i>Annals of Maxillofacial Surgery</i> , 2019, 9, 28.	0.2	4
72	What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?. <i>Indian Journal of Medical Research</i> , 2019, 149, 309.	0.4	110

#	ARTICLE	IF	CITATIONS
73	Performance of the TB-LAMP diagnostic assay in reference laboratories: Results from a multicentre study. <i>International Journal of Infectious Diseases</i> , 2018, 68, 44-49.	1.5	21
74	Pan-tuberculosis regimens: an argument against. <i>Lancet Respiratory Medicine</i> , 2018, 6, 240-242.	5.2	17
75	Correlation of Xpert MTB/RIF with measures to assess Mycobacterium tuberculosis bacillary burden in high HIV burden areas of Southern Africa. <i>Scientific Reports</i> , 2018, 8, 5201.	1.6	31
76	Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment. <i>Respirology</i> , 2018, 23, 656-673.	1.3	159
77	Regulatory T Cells Subvert Mycobacterial Containment in Patients Failing Extensively Drug-Resistant Tuberculosis Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 104-116.	2.5	28
78	Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis. <i>Nature Genetics</i> , 2018, 50, 307-316.	9.4	271
79	Evaluation of a Urine-Based Rapid Molecular Diagnostic Test with Potential to Be Used at Point-of-Care for Pulmonary Tuberculosis. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 215-224.	1.2	25
80	False-Positive Xpert MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical Outcomes. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	78
81	Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. <i>European Respiratory Journal</i> , 2018, 51, 1800544.	3.1	91
82	Time to revise WHO-recommended definitions of MDR-TB treatment outcomes. <i>Lancet Respiratory Medicine</i> , 2018, 6, 246-248.	5.2	11
83	Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?. <i>Respirology</i> , 2018, 23, 36-45.	1.3	52
84	Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. <i>Journal of Thoracic Disease</i> , 2018, 10, 3102-3118.	0.6	34
85	Xpert <sup>®</sup> MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. <i>The Cochrane Library</i> , 2018, 8, CD012768.	1.5	153
86	1275. Will an App-Optimized HIV Self-testing Strategy Work for South Africans? Results From a Large Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, S388-S388.	0.4	1
87	Revising the definition of extensively drug-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 893-895.	5.2	12
88	d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. <i>Clinical Infectious Diseases</i> , 2018, 67, S308-S316.	2.9	45
89	The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, S336-S341.	2.9	26
90	C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial. <i>PLoS ONE</i> , 2018, 13, e0204554.	1.1	42

#	ARTICLE	IF	CITATIONS
91	Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase. <i>Scientific Reports</i> , 2018, 8, 15382.	1.6	75
92	â€˜Mind the gap': detecting the missing TB cases through active case finding. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 1115-1115.	0.6	1
93	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834.	6.3	452
94	M/XDRâ€™TB treatment perspective: How to avoid mountains of pills via digital technologies â€™ Reply. <i>Respirology</i> , 2018, 23, 637-637.	1.3	0
95	Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. <i>Clinical Microbiology Reviews</i> , 2018, 31, .	5.7	353
96	Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1208-1219.	2.5	130
97	Tuberculous meningitis is associated with higher cerebrospinal HIV-1 viral loads compared to other HIV-1-associated meningitides. <i>PLoS ONE</i> , 2018, 13, e0192060.	1.1	11
98	Impact of nicotine replacement therapy as an adjunct to anti-tuberculosis treatment and behaviour change counselling in newly diagnosed pulmonary tuberculosis patients: an open-label, randomised controlled trial. <i>Scientific Reports</i> , 2018, 8, 8828.	1.6	13
99	Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	29
100	South African guideline for the management of community-acquired pneumonia in adults. <i>Southern African Journal of Infectious Diseases</i> , 2018, 33, 5-27.	0.3	1
101	Lung health in Africa: African solutions for African challenges - to infinity and beyond. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2018, 24, .	0.3	0
102	Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control. <i>Microbiology Spectrum</i> , 2017, 5, .	1.2	42
103	Endoscopic Valve Therapy: A New Therapeutic Approach for Otherwise Incurable Tuberculosis?. <i>Respiration</i> , 2017, 93, 79-80.	1.2	1
104	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. <i>European Respiratory Journal</i> , 2017, 49, 1700387.	3.1	233
105	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 291-360.	5.2	459
106	Anaerobic Bacterial Fermentation Products Increase Tuberculosis Risk in Antiretroviral-Drug-Treated HIV Patients. <i>Cell Host and Microbe</i> , 2017, 21, 530-537.e4.	5.1	95
107	Design and use of mouse control DNA for DNA biomarker extraction and PCR detection from urine: Application for transrenal Mycobacterium tuberculosis DNA detection. <i>Journal of Microbiological Methods</i> , 2017, 136, 65-70.	0.7	6
108	Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 441-450.	4.6	71

#	ARTICLE	IF	CITATIONS
109	Removing the bottleneck in whole genome sequencing of <i>Mycobacterium tuberculosis</i> for rapid drug resistance analysis: a call to action. <i>International Journal of Infectious Diseases</i> , 2017, 56, 130-135.	1.5	49
110	The Multistep Tuberculosis Diagnostic Cascade. More Than Meets the Eye. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 809-811.	2.5	0
111	Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis. <i>Science Advances</i> , 2017, 3, e1701102.	4.7	56
112	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 785-794.	5.2	201
113	Do digital innovations for HIV and sexually transmitted infections work? Results from a systematic review (1996-2017). <i>BMJ Open</i> , 2017, 7, e017604.	0.8	116
114	Early morning urine collection to improve urinary lateral flow LAM assay sensitivity in hospitalised patients with HIV-TB co-infection. <i>BMC Infectious Diseases</i> , 2017, 17, 339.	1.3	15
115	Making HIV testing work at the point of care in South Africa: a qualitative study of diagnostic practices. <i>BMC Health Services Research</i> , 2017, 17, 408.	0.9	19
116	Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. <i>Clinical Microbiology and Infection</i> , 2017, 23, 131-140.	2.8	47
117	A standardised method for interpreting the association between mutations and phenotypic drug resistance in <i>Mycobacterium tuberculosis</i> . <i>European Respiratory Journal</i> , 2017, 50, 1701354.	3.1	273
118	Using Urine Lipoarabinomannan (LAM) in Practice: The Incremental Yield of Urine LAM and Xpert MTB/RIF Testing in Hospitalized HIV-Infected Patients. <i>Chest</i> , 2017, 152, A200.	0.4	0
119	Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control. , 2017, , 389-410.		1
120	Designing and Evaluating Interventions to Halt the Transmission of Tuberculosis. <i>Journal of Infectious Diseases</i> , 2017, 216, S654-S661.	1.9	26
121	A comparison of the conditional inference survival forest model to random survival forests based on a simulation study as well as on two applications with time-to-event data. <i>BMC Medical Research Methodology</i> , 2017, 17, 115.	1.4	50
122	Diagnosing tuberculosis in hospitalized HIV-infected individuals who cannot produce sputum: is urine lipoarabinomannan testing the answer?. <i>BMC Infectious Diseases</i> , 2017, 17, 803.	1.3	21
123	The tip of the iceberg: Alarming increase in the detection of MDR-TB. <i>South African Respiratory Journal</i> , 2017, 23, 26.	0.0	0
124	South African guideline for the management of community-acquired pneumonia in adults. <i>Journal of Thoracic Disease</i> , 2017, 9, 1469-1502.	0.6	63
125	Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically curable tuberculosis: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 269-281.	5.2	106
126	Impact of correcting the lymphocyte count to improve the sensitivity of TB antigen-specific peripheral blood-based quantitative T cell assays (T-SPOT.Â®TB and QFT-GIT). <i>Journal of Thoracic Disease</i> , 2016, 8, 482-489.	0.6	3



#	ARTICLE	IF	CITATIONS
127	Recommendations for the management of idiopathic pulmonary fibrosis in South Africa: a position statement of the South African Thoracic Society. <i>Journal of Thoracic Disease</i> , 2016, 8, 3711-3719.	0.6	7
128	Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons. <i>British Journal of Dermatology</i> , 2016, 175, 150-156.	1.4	43
129	The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. <i>Scientific Reports</i> , 2016, 6, 32924.	1.6	15
130	An automated tuberculosis screening strategy combining X-ray-based computer-aided detection and clinical information. <i>Scientific Reports</i> , 2016, 6, 25265.	1.6	100
131	The diagnostic accuracy of the MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates. <i>Scientific Reports</i> , 2016, 6, 17850.	1.6	45
132	The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs. <i>Genome Medicine</i> , 2016, 8, 132.	3.6	44
133	Recombination in <i>pe/ppe</i> genes contributes to genetic variation in <i>Mycobacterium tuberculosis</i> lineages. <i>BMC Genomics</i> , 2016, 17, 151.	1.2	62
134	GenoType <sup>®</sup> MTBDRsl assay for resistance to second-line anti-tuberculosis drugs. <i>The Cochrane Library</i> , 2016, 2016, CD010705.	1.5	42
135	Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw130.	0.4	14
136	Getting bang for buck in the latent tuberculosis care cascade. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1209-1210.	4.6	5
137	Tuberculosis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16076.	18.1	830
138	The epidemiology of tuberculosis in health care workers in South Africa: a systematic review. <i>BMC Health Services Research</i> , 2016, 16, 416.	0.9	44
139	Longitudinal assessment of health related quality of life of HIV infected patients treated for tuberculosis and HIV in a high burden setting. <i>Quality of Life Research</i> , 2016, 25, 3067-3076.	1.5	6
140	Tuberculosis and Poncet's disease: the many faces of an old enemy. <i>Lancet</i> , The, 2016, 387, 618.	6.3	63
141	Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?. <i>Clinical Infectious Diseases</i> , 2016, 62, 995-1001.	2.9	112
142	Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1187-1197.	6.3	211
143	Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. <i>European Respiratory Journal</i> , 2016, 47, 919-928.	3.1	52
144	Tuberculosis. <i>Lancet</i> , The, 2016, 387, 1211-1226.	6.3	480

#	ARTICLE	IF	CITATIONS
145	In Vivo Molecular Dissection of the Effects of HIV-1 in Active Tuberculosis. PLoS Pathogens, 2016, 12, e1005469.	2.1	46
146	Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments. Scientific Reports, 2015, 4, 5658.	1.6	100
147	Time for the Global Rollout of Endoscopic Lung Volume Reduction. Respiration, 2015, 90, 430-440.	1.2	19
148	Comparative performance characteristics of the urine lipoarabinomannan strip test and sputum smear microscopy in hospitalized HIV-infected patients with suspected tuberculosis in Harare, Zimbabwe. BMC Infectious Diseases, 2015, 16, 20.	1.3	15
149	Lifestyle, attitudes and needs of uncured XDR-TB patients living in the communities of South Africa: a qualitative study. Tropical Medicine and International Health, 2015, 20, 1155-1161.	1.0	10
150	Indications for the use of bronchial thermoplasty in severe asthma. South African Medical Journal, 2015, 105, 808.	0.2	0
151	High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis. PLoS ONE, 2015, 10, e0123655.	1.1	19
152	Incidence of occupational latent tuberculosis infection in South African healthcare workers. European Respiratory Journal, 2015, 45, 1364-1373.	3.1	41
153	Automatic Detection of Tuberculosis in Chest Radiographs Using a Combination of Textural, Focal, and Shape Abnormality Analysis. IEEE Transactions on Medical Imaging, 2015, 34, 2429-2442.	5.4	62
154	False-negative interferon- $\gamma$ release assay results in active tuberculosis: a TBNET study. European Respiratory Journal, 2015, 45, 279-283.	3.1	36
155	Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial. Lancet Respiratory Medicine, 2015, 3, 621-630.	5.2	40
156	Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases. Journal of Antimicrobial Chemotherapy, 2015, 70, 2648-2651.	1.3	19
157	Impact of tuberculosis treatment and antiretroviral therapy on serial RD-1-specific quantitative T-cell readouts (QuantiFERON-TB Gold In-Tube), and relationship to treatment-related outcomes and bacterial burden. International Journal of Infectious Diseases, 2015, 36, 46-53.	1.5	1
158	HIV associated Lymphocytic Interstitial Pneumonia: a clinical, histological and radiographic study from an HIV endemic resource-poor setting. BMC Pulmonary Medicine, 2015, 15, 38.	0.8	15
159	Biologic therapy for rheumatoid arthritis in developing countries—a place for non-TNF inhibitors as first-line treatment?. Rheumatology, 2015, 54, 208-209.	0.9	11
160	Compounding diagnostic delays: a qualitative study of point-of-care testing in South Africa. Tropical Medicine and International Health, 2015, 20, 493-500.	1.0	30
161	Psychological distress and its relationship with non-adherence to TB treatment: a multicentre study. BMC Infectious Diseases, 2015, 15, 253.	1.3	49
162	Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing. BMC Infectious Diseases, 2015, 15, 262.	1.3	27

#	ARTICLE	IF	CITATIONS
163	A Survey on Use of Rapid Tests and Tuberculosis Diagnostic Practices by Primary Health Care Providers in South Africa: Implications for the Development of New Point-of-Care Tests. PLoS ONE, 2015, 10, e0141453.	1.1	14
164	Recommendations for the use of bronchial thermoplasty in the management of severe asthma. South African Medical Journal, 2015, 105, 726-32.	0.2	1
165	Cigarette smoke impairs cytokine responses and BCG containment in alveolar macrophages. Thorax, 2014, 69, 363-370.	2.7	67
166	Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa. The Lancet Global Health, 2014, 2, e554-e556.	2.9	10
167	The diagnostic accuracy of the GenoType <sup>®</sup> MTBDR <sub>sl</sub> assay for the detection of resistance to second-line anti-tuberculosis drugs. , 2014, , CD010705.		72
168	Sputum induction to aid diagnosis of smear-negative or sputum-scarce tuberculosis in adults in HIV-endemic settings. European Respiratory Journal, 2014, 43, 185-194.	3.1	35
169	Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon- $\gamma$ in a high burden setting: a prospective study. BMC Medicine, 2014, 12, 101.	2.3	75
170	Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet, The, 2014, 383, 1230-1239.	6.3	211
171	Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clinical Microbiology Reviews, 2014, 27, 3-20.	5.7	662
172	Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respiratory Medicine, the, 2014, 2, 321-338.	5.2	237
173	TRIM5 $\alpha$ and TRIM22 Are Differentially Regulated According to HIV-1 Infection Phase and Compartment. Journal of Virology, 2014, 88, 4291-4303.	1.5	21
174	Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet, The, 2014, 383, 424-435.	6.3	379
175	Comparison of Amplicor and GeneXpert MTB/RIF Tests for Diagnosis of Tuberculous Meningitis. Journal of Clinical Microbiology, 2014, 52, 3777-3780.	1.8	25
176	Better treatment of XDR tuberculosis needed in South Africa – Author's reply. Lancet, The, 2014, 384, 582.	6.3	8
177	Comparison of same day diagnostic tools including Gene Xpert and unstimulated IFN- $\gamma$ for the evaluation of pleural tuberculosis: a prospective cohort study. BMC Pulmonary Medicine, 2014, 14, 58.	0.8	60
178	Xpert MTB/RIF as a Measure of Sputum Bacillary Burden. Variation by HIV Status and Immunosuppression. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1426-1434.	2.5	64
179	Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?. Lancet Infectious Diseases, The, 2014, 14, 527-532.	4.6	141
180	Detecting active pulmonary tuberculosis with a breath test using nanomaterial-based sensors. European Respiratory Journal, 2014, 43, 1522-1525.	3.1	88

#	ARTICLE	IF	CITATIONS
181	The identification of tuberculosis biomarkers in human urine samples. <i>European Respiratory Journal</i> , 2014, 43, 1719-1729.	3.1	56
182	The medical and surgical treatment of drug-resistant tuberculosis. <i>Journal of Thoracic Disease</i> , 2014, 6, 186-95.	0.6	37
183	Aspergilloma and the surgeon. <i>Journal of Thoracic Disease</i> , 2014, 6, 202-9.	0.6	46
184	Crosstalk between the thoracic physician and the surgeon: perspectives on pulmonary infections, malignancy and chest surgery. <i>Journal of Thoracic Disease</i> , 2014, 6, 181.	0.6	4
185	Regulatory T Cells Attenuate Mycobacterial Stasis in Alveolar and Blood-derived Macrophages from Patients with Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1249-1258.	2.5	68
186	EDCTP regional networks of excellence: initial merits for planned clinical trials in Africa. <i>BMC Public Health</i> , 2013, 13, 258.	1.2	24
187	Rapid diagnosis of pulmonary tuberculosis in African children in a primary care setting by use of Xpert MTB/RIF on respiratory specimens: a prospective study. <i>The Lancet Global Health</i> , 2013, 1, e97-e104.	2.9	82
188	Comparison of two methods for acquisition of sputum samples for diagnosis of suspected tuberculosis in smear-negative or sputum-scarce people: a randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2013, 1, 471-478.	5.2	52
189	Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. <i>BMC Infectious Diseases</i> , 2013, 13, 407.	1.3	68
190	Point-of-care diagnosis of tuberculosis: Past, present and future. <i>Respirology</i> , 2013, 18, 217-232.	1.3	127
191	Scoring systems using chest radiographic features for the diagnosis of pulmonary tuberculosis in adults: a systematic review. <i>European Respiratory Journal</i> , 2013, 42, 480-494.	3.1	59
192	Rationalizing Use of Fluoroquinolones and Pyrazinamide in the Battle against Multidrug-Resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 10-11.	2.5	3
193	HIV self-testing strategy: the middle road. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 639-642.	1.5	12
194	Diagnostic Accuracy of Quantitative PCR (Xpert MTB/RIF) for Tuberculous Meningitis in a High Burden Setting: A Prospective Study. <i>PLoS Medicine</i> , 2013, 10, e1001536.	3.9	142
195	Supervised and Unsupervised Self-Testing for HIV in High- and Low-Risk Populations: A Systematic Review. <i>PLoS Medicine</i> , 2013, 10, e1001414.	3.9	285
196	Relationship between chemokine receptor expression, chemokine levels and HIV-1 replication in the lungs of persons exposed to Mycobacterium tuberculosis. <i>European Journal of Immunology</i> , 2013, 43, 540-549.	1.6	19
197	Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. <i>Thorax</i> , 2013, 68, 1043-1051.	2.7	93
198	South African tobacco smoking cessation clinical practice guideline. <i>South African Medical Journal</i> , 2013, 103, 869.	0.2	29

#	ARTICLE	IF	CITATIONS
199	What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?. PLoS ONE, 2013, 8, e54587.	1.1	187
200	Increased Production of IL-4 and IL-12p40 from Bronchoalveolar Lavage Cells Are Biomarkers of Mycobacterium tuberculosis in the Sputum. PLoS ONE, 2013, 8, e59461.	1.1	16
201	Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa. PLoS ONE, 2013, 8, e63057.	1.1	71
202	Development of a Simple Reliable Radiographic Scoring System to Aid the Diagnosis of Pulmonary Tuberculosis. PLoS ONE, 2013, 8, e54235.	1.1	34
203	Can Point-of-Care Urine LAM Strip Testing for Tuberculosis Add Value to Clinical Decision Making in Hospitalised HIV-Infected Persons?. PLoS ONE, 2013, 8, e54875.	1.1	32
204	Will an Unsupervised Self-Testing Strategy for HIV Work in Health Care Workers of South Africa? A Cross Sectional Pilot Feasibility Study. PLoS ONE, 2013, 8, e79772.	1.1	73
205	Characteristics of Xpert MTB/RIF-Negative Patients With Pulmonary Tuberculosis. Clinical Infectious Diseases, 2012, 55, 472-473.	2.9	5
206	Lichenoid drug reaction to antituberculosis drugs treated through with topical steroids and phototherapy. Journal of Antimicrobial Chemotherapy, 2012, 67, 2535-2537.	1.3	17
207	The Use of an Automated Quantitative Polymerase Chain Reaction (Xpert MTB/RIF) to Predict the Sputum Smear Status of Tuberculosis Patients. Clinical Infectious Diseases, 2012, 54, 384-388.	2.9	41
208	Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?. European Respiratory Journal, 2012, 40, 161-168.	3.1	60
209	The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?. Lancet, The, 2012, 379, 773-775.	6.3	88
210	Sanatoria for drug-resistant tuberculosis: an outdated response – Authors' reply. Lancet, The, 2012, 379, 2148-2149.	6.3	2
211	Urine antigen test for diagnosis of HIV-associated tuberculosis. Lancet Infectious Diseases, The, 2012, 12, 825.	4.6	5
212	Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future. Expert Review of Anti-Infective Therapy, 2012, 10, 475-486.	2.0	57
213	Correlation of Mycobacterium Tuberculosis Specific and Non-Specific Quantitative Th1 T-Cell Responses with Bacillary Load in a High Burden Setting. PLoS ONE, 2012, 7, e37436.	1.1	33
214	The Diagnostic Accuracy of Urine-Based Xpert MTB/RIF in HIV-Infected Hospitalized Patients Who Are Smear-Negative or Sputum Scarce. PLoS ONE, 2012, 7, e39966.	1.1	75
215	Selection and Application of ssDNA Aptamers to Detect Active TB from Sputum Samples. PLoS ONE, 2012, 7, e46862.	1.1	57
216	Use of Anti-Retroviral Therapy in Tuberculosis Patients on Second-Line Anti-TB Regimens: A Systematic Review. PLoS ONE, 2012, 7, e47370.	1.1	29

#	ARTICLE	IF	CITATIONS
217	Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. <i>European Respiratory Journal</i> , 2012, 40, 1211-1220.	3.1	117
218	ICU-Associated <i>Acinetobacter baumannii</i> Colonisation/Infection in a High HIV-Prevalence Resource-Poor Setting. <i>PLoS ONE</i> , 2012, 7, e52452.	1.1	29
219	Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 132-140.	2.5	283
220	Xpert MTB/RIF test for tuberculosis. <i>Lancet</i> , The, 2011, 378, 481.	6.3	11
221	Comparison of Quantitative Techniques including Xpert MTB/RIF to Evaluate Mycobacterial Burden. <i>PLoS ONE</i> , 2011, 6, e28815.	1.1	87
222	Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. <i>Current Opinion in Rheumatology</i> , 2011, 23, 377-384.	2.0	59
223	Viewpoint: Scientific dogmas, paradoxes and mysteries of latent <i>Mycobacterium tuberculosis</i> infection. <i>Tropical Medicine and International Health</i> , 2011, 16, 79-83.	1.0	51
224	Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. <i>Tuberculosis</i> , 2011, 91, 587-593.	0.8	71
225	Transcriptional profiling of innate and adaptive human immune responses to mycobacteria in the tuberculin skin test. <i>European Journal of Immunology</i> , 2011, 41, 3253-3260.	1.6	27
226	Human Lung Immunity against <i>Mycobacterium tuberculosis</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 696-707.	2.5	98
227	Novel Developments in the Epidemic of Human Immunodeficiency Virus and Tuberculosis Coinfection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 987-997.	2.5	29
228	Comparative Utility of Cytokine Levels and Quantitative RD-1-Specific T Cell Responses for Rapid Immunodiagnosis of Tuberculous Meningitis. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3971-3976.	1.8	14
229	Functional Capacity of <i>Mycobacterium tuberculosis</i> -Specific T Cell Responses in Humans Is Associated with Mycobacterial Load. <i>Journal of Immunology</i> , 2011, 187, 2222-2232.	0.4	305
230	Rapid and Accurate Detection of <i>Mycobacterium tuberculosis</i> in Sputum Samples by Cepheid Xpert MTB/RIF Assay—A Clinical Validation Study. <i>PLoS ONE</i> , 2011, 6, e20458.	1.1	140
231	A historical review of XDR tuberculosis in the Western Cape province of South Africa. <i>South African Medical Journal</i> , 2011, 101, 636-8.	0.2	1
232	Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 262-270.	1.2	100
233	Quantitative Pulmonary T-Cell Responses for the Diagnosis of Active Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 289-289.	2.5	2
234	High Incidence of Hospital Admissions With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Among South African Health Care Workers. <i>Annals of Internal Medicine</i> , 2010, 153, 516.	2.0	151

#	ARTICLE	IF	CITATIONS
235	Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. <i>BMC Pulmonary Medicine</i> , 2010, 10, 7.	0.8	79
236	World TB Day 2010 - New innovations are required for enhancing the global fight against Tuberculosis: the "Captain of all these men of death"™. <i>Tropical Medicine and International Health</i> , 2010, 15, 274-276.	1.0	4
237	Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. <i>Tropical Medicine and International Health</i> , 2010, 15, 1052-1066.	1.0	62
238	Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. <i>Tropical Medicine and International Health</i> , 2010, 15, 1179-1184.	1.0	32
239	The immunology of tuberculosis: From bench to bedside. <i>Respirology</i> , 2010, 15, 433-450.	1.3	155
240	Feasibility and Diagnostic Utility of Antigen-Specific Interferon- $\gamma$ Responses for Rapid Immunodiagnosis of Tuberculosis Using Induced Sputum. <i>PLoS ONE</i> , 2010, 5, e10389.	1.1	12
241	Comparison of a Clinical Prediction Rule and a LAM Antigen-Detection Assay for the Rapid Diagnosis of TBM in a High HIV Prevalence Setting. <i>PLoS ONE</i> , 2010, 5, e15664.	1.1	47
242	Cerebrospinal T-Cell Responses Aid in the Diagnosis of Tuberculous Meningitis in a Human Immunodeficiency Virus- and Tuberculosis-Endemic Population. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 569-577.	2.5	65
243	Extensively Drug-resistant Tuberculosis: Epidemiology and Management Challenges. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 705-725.	1.9	50
244	Tuberculosis in association with HIV/AIDS emerges as a major nonobstetric cause of maternal mortality in Sub-Saharan Africa. <i>International Journal of Gynecology and Obstetrics</i> , 2010, 108, 181-183.	1.0	54
245	Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. <i>Lancet, The</i> , 2010, 375, 1830-1843.	6.3	866
246	Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. <i>Lancet, The</i> , 2010, 375, 1798-1807.	6.3	225
247	Extensively drug-resistant tuberculosis in South Africa " Authors' reply. <i>Lancet, The</i> , 2010, 376, 681-682.	6.3	0
248	Clinical Utility of a Commercial LAM-ELISA Assay for TB Diagnosis in HIV-Infected Patients Using Urine and Sputum Samples. <i>PLoS ONE</i> , 2010, 5, e9848.	1.1	117
249	Within-Subject Variability of Interferon- $\gamma$ Assay Results for Tuberculosis and Boosting Effect of Tuberculin Skin Testing: A Systematic Review. <i>PLoS ONE</i> , 2009, 4, e8517.	1.1	171
250	Utility of quantitative T-cell responses versus unstimulated interferon- $\gamma$ for the diagnosis of pleural tuberculosis. <i>European Respiratory Journal</i> , 2009, 34, 1118-1126.	3.1	86
251	HIV-1 Infection Impairs the Bronchoalveolar T-Cell Response to Mycobacteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 1262-1270.	2.5	138
252	Quantitative lung T cell responses aid the rapid diagnosis of pulmonary tuberculosis. <i>Thorax</i> , 2009, 64, 847-853.	2.7	55

#	ARTICLE	IF	CITATIONS
253	Within-Subject Variability and Boosting of T-Cell Interferon- $\gamma$ Responses after Tuberculin Skin Testing. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 49-58.	2.5	169
254	Utility of a novel lipoarabinomannan assay for the diagnosis of tuberculous meningitis in a resource-poor high-HIV prevalence setting. <i>Cerebrospinal Fluid Research</i> , 2009, 6, 13.	0.5	37
255	TB diagnostic tests: how do we figure out their costs?. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 723-733.	2.0	29
256	Multidrug- and Extensively Drug-resistant Tuberculosis in Africa and South America: Epidemiology, Diagnosis and Management in Adults and Children. <i>Clinics in Chest Medicine</i> , 2009, 30, 667-683.	0.8	50
257	T-cell interferon- $\gamma$ release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 188-200.	1.2	169
258	Clinical Diagnostic Utility of IP-10 and LAM Antigen Levels for the Diagnosis of Tuberculous Pleural Effusions in a High Burden Setting. <i>PLoS ONE</i> , 2009, 4, e4689.	1.1	70
259	Extensively drug-resistant <i>Mycobacterium tuberculosis</i> : what are these bugs up to in India?. <i>Indian Journal of Medical Research</i> , 2009, 130, 357-8.	0.4	1
260	Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients Receiving Antiretroviral Therapy. <i>Drugs</i> , 2008, 68, 191-208.	4.9	144
261	T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 428-438.	4.6	167
262	Lethal interaction: the colliding epidemics of tobacco and tuberculosis. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 385-391.	2.0	80
263	Interpretation of <i>Mycobacterium tuberculosis</i> antigen-specific IFN- $\gamma$ release assays (T-SPOT.TB) and factors that may modulate test results. <i>Journal of Infection</i> , 2007, 55, 169-173.	1.7	56
264	The stability of mRNA encoding IL-4 is increased in pulmonary tuberculosis, while stability of mRNA encoding the antagonistic splice variant, IL-4 $\beta$ 2, is not. <i>Tuberculosis</i> , 2007, 87, 237-241.	0.8	18
265	New tools and emerging technologies for the diagnosis of tuberculosis: Part II. Active tuberculosis and drug resistance. <i>Expert Review of Molecular Diagnostics</i> , 2006, 6, 423-432.	1.5	168
266	Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. <i>Journal of Occupational Medicine and Toxicology</i> , 2006, 1, 7.	0.9	85
267	Expression of IL-4 mRNA in peripheral blood mononuclear cells from normal donors in relation to expression of TLR2. <i>Immunology Letters</i> , 2006, 106, 194-197.	1.1	0
268	New tools and emerging technologies for the diagnosis of tuberculosis: Part I. Latent tuberculosis. <i>Expert Review of Molecular Diagnostics</i> , 2006, 6, 413-422.	1.5	223
269	Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not. <i>Tuberculosis</i> , 2006, 86, 152-162.	0.8	40
270	<i>Mycobacterium tuberculosis</i> Induces Selective Up-Regulation of TLRs in the Mononuclear Leukocytes of Patients with Active Pulmonary Tuberculosis. <i>Journal of Immunology</i> , 2006, 176, 3010-3018.	0.4	45



#	ARTICLE	IF	CITATIONS
271	Utility of the antigen-specific interferon- $\gamma$ assay for the management of tuberculosis. <i>Current Opinion in Pulmonary Medicine</i> , 2005, 11, 195-202.	1.2	109
272	Expression of a novel cytokine, IL-4delta2, in HIV and HIV-associated tuberculosis co-infection. <i>Aids</i> , 2005, 19, 1601-1606.	1.0	25
273	Immune responses to tuberculosis in developing countries: implications for new vaccines. <i>Nature Reviews Immunology</i> , 2005, 5, 661-667.	10.6	149
274	Reply to Lu et al.. <i>Journal of Infectious Diseases</i> , 2005, 192, 1674-1675.	1.9	0
275	In Vivo and In Vitro Studies of a Novel Cytokine, Interleukin 4 $\delta$ 2, in Pulmonary Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 501-508.	2.5	60
276	Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. <i>Aids</i> , 2005, 19, 2038-2041.	1.0	112
277	Lung Remodeling in Pulmonary Tuberculosis. <i>Journal of Infectious Diseases</i> , 2005, 192, 1201-1209.	1.9	207
278	Validation of housekeeping genes for normalizing RNA expression in real-time PCR. <i>BioTechniques</i> , 2004, 37, 112-119.	0.8	838
279	Smoking is Not Beneficial for Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 821-821.	2.5	9
280	Outcome of HIV-associated Tuberculosis in the Era of Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2004, 190, 1670-1676.	1.9	181
281	IL-4 in tuberculosis: implications for vaccine design. <i>Trends in Immunology</i> , 2004, 25, 483-488.	2.9	167
282	Type 2 Cytokines in Respiratory Syncytial Virus Bronchiolitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 1167-1168.	2.5	4
283	Peripheral T Cell Interferon- $\gamma$ Responses and Latent Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 97-98.	2.5	5